RAS Dialogue Blog
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
Targeted Therapies, Tooth Extraction, and MetastasisResistance often develops to targeted cancer drugs. Mouse studies indicate that dying cancer cells secrete signals that help other cancer cells survive.
-
Mutations in Human Cancers Through the Lens of KRASExome sequences from The Cancer Genome Atlas were analyzed for the types of missense mutations in KRAS that were associated with missense mutations in other commonly mutated genes.
-
Nanotechnology for Treating Cancer: Pitfalls and Bridges on the Path to NanomedicinesDespite their promise, only a few nano-formulated drugs are used in humans. The NCI Nanotechnology Characterization Lab helps companies and academic investigators maximize their chance of successful clinical use.
-
Ras: Do We Know Its Structure Well Enough?Carla Mattos discusses how subtle changes in distant parts of RAS molecules may influence the conversion of GTP to GDP that is fundamental to RAS signaling.
-
Enzymology of GTP-competitive RAS inhibitorsRAS molecules have affinities for GTP and GDP that are in the picomolar range. Ken Westover argues that covalent inhibitors of RAS are logical drug candidates.